Interleukin-1 blocking agents for treating COVID-19 (search done on 5 November 2021)
Citation: Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database of Systematic Reviews. 2022;(1):CD015308.
Language: Abstract available in EN / ES / FA / FR / ZA; Plain language summary available in EN / ES / FA / FR / ZA; Full text available in EN; Podcast available in EN / FR.
Free to view: Yes.
What is this? Interleukin-1 blocking agents have been suggested as possible treatments for COVID-19 patients.
In this Cochrane rapid living review, the authors searched for randomized trials of interleukin-1 blocking agents for treating COVID-19 patients. They did not restrict their searches by language of publication and did the most recent search on 5 November 2021. They included 4 trials of anakinra and 2 trials of canakinumab, and identified a further 16 registered trials with no results available at the time of this version of the review.
What was found: At the time of this version of this living review, there was insufficient evidence to show that medicines that block interleukin‐1 are effective for treating COVID-19 patients.
This summary was prepared by, edited by, and finalised by Mike Clarke.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone. The text can be shared and re-used without charge, citing Evidence Aid as the source and noting the date on which you took the text.
We’ve already reached tens of thousands of people with plain language summaries of systematic reviews. If you’d like to help us to continue our work, please consider a donation.
Donate with PayPal
You can also donate through the Charities Aid Foundation (CAF) here. If you are based in the USA and want to make a tax-deductable donation, please donate to Evidence Aid via the British Schools and Universities Foundation.